Shareholder Information

Shareholder Information

A new chapter for Vifor Pharma Group

Dear Shareholders,  

The official change of our company name from Galenica Ltd to Vifor Pharma Ltd. was approved by shareholders at the 89th Annual General Meeting on 11 May 2017. Our new name constitutes another major step on our journey toward becoming a fully focused specialty pharmaceuticals company on improving the lives of patients through global leadership in iron deficiency, nephrology and cardio-renal therapies.

The decision to sell off our historical core business, Galenica Santé, through an extremely successful IPO (second largest worldwide up to now this year) was taken to maximise Vifor Pharma’s growth potential and to build on our proud heritage of creating value for shareholders over many decades.

With our ‘Milestone 2020’ plan we are entering a new phase in the extraordinary life of our company. ‘Milestone 2020’ will give us a strategic, very strong position as a global specialty pharmaceuticals company. Together with our already attractive portfolio of products either on the market or ready for launch and the fact that we have no net debt and between CHF 400 to 500 million on our balance sheet, we have the foundation for long-term success.

By investing in our company now, we are fully leveraging the potential of Vifor Pharma Group.

We are confident that with your support, Vifor Pharma Group can achieve our ambition of continuing to deliver value for our shareholders, creating real opportunities for our employees and above all helping transform the lives of patients around the world.

Kind regards,  

Etienne Jornod
Executive Chairman



FAQ for individual shareholders